Exact Sciences (NASDAQ: EXAS) reported Q4 EPS of ($0.34), $0.05 better than the analyst estimate of ($0.39). Revenue for the quarter came in at $35.2 million versus the consensus estimate of $33.19 million.

2017 Outlook

"We intend to build on last year's success by contracting with additional payers, increasing awareness about Cologuard's inclusion in health care quality measures, and making it easier for physicians to order our test," Conroy said. "Based on the financial strength of Exact Sciences and the power of the Cologuard technology platform, we will continue investing prudently to support our growth and bring new cancer diagnostics to patients."

The company anticipates revenue of $170-$180 million and Cologuard volume of at least 415,000 completed tests during 2017. During the first quarter of 2017, the company expects Cologuard volume of at least 88,000 completed tests.

For earnings history and earnings-related data on Exact Sciences (EXAS) click here.